Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2407-2413

  Asklund, Thomas ^a   Kvarnbrink, Samuel ^a   Holmlund, Camilla ^a   Wibom, Carl ^a   Bergenheim, Tommy ^a   Henriksson, Roger ^a   Hedman, Håkan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

GL15 cells; Glioblastoma; HDAC inhibitor; Proteasome inhibitor; R11 stem cells; Stem cells; TB101; U251 MG

Indexed keywords

4 PHENYLBUTYRIC ACID; BORTEZOMIB; PROPIDIUM IODIDE; VALPROIC ACID; VORINOSTAT;

ARTICLE; BRIGHT FIELD MICROSCOPY; CANCER CELL CULTURE; CANCER STEM CELL; CELL CLONING; CELL DEATH; CELL KILLING; CELL LABELING; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; PHENYLBUTYRATES; PYRAZINES; VALPROIC ACID;

EID: 84865678346     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996, 2005. (Pubitemid 40349501)
2. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414(6859): 105-111, 2001. (Pubitemid 33041634)
3. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18): 5821-5828, 2003. (Pubitemid 37187480)
4. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67(9): 4010-4015, 2007. (Pubitemid 46815044)
5. Son MJ, Woolard K, Nam DH, Lee J and Fine HA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4(5): 440-452, 2009.
6. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB and Rich JN: Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6(5): 421-432, 2010.
7. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/AKT pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4(3): 226-235, 2009.
8. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19): 7011-7021, 2004. (Pubitemid 39331011)
9. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK and Fine HA: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9(5): 391-403, 2006. (Pubitemid 43668737)
10. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A and Dirks P: Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4(6): 568-580, 2009.
11. de Bettignies G and Coux O: Proteasome inhibitors: Dozens of molecules and still counting. Biochimie 92(11): 1530-1545, 2010.
12. Adams J, Palombella VJ and Elliott PJ: Proteasome inhibition: a new strategy in cancer treatment. Investigational new drugs. 18(2): 109-121, 2000. (Pubitemid 30261285)
13. Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S and Olson JJ: Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 100(1): 95-103, 2010.
14. Carew JS, Giles FJ and Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer lett 269(1): 7-17, 2008.
15. Lin HY, Chen CS, Lin SP and Weng JR: Targeting histone deacetylase in cancer therapy. Med Res Rev 26(4): 397-413, 2006.
16. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37): 5541-5552, 2007. (Pubitemid 47255934)
17. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF, Jr., Zwiebel J and Buckner JC: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27(12): 2052-2058, 2009.
18. Papi A, Ferreri AM, Rocchi P, Guerra F and Orlandi M: Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Res 30(2): 535-540, 2010.
19. Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K and Tofilon PJ: Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14(17): 5410-5415, 2008.
20. Gore SD and Carducci MA: Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert opinion on investigational drugs 9(12): 2923-2934, 2000.
21. Asklund T, Appelskog IB, Ammerpohl O, Ekstrom TJ and Almqvist PM: Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells. Eur J Cancer 40(7): 1073-1081, 2004. (Pubitemid 38496266)
22. Khan Z, Akhtar M, Asklund T, Juliusson B, Almqvist PM and Ekstrom TJ: HDAC inhibition amplifies gap junction communication in neural progenitors: potential for cell-mediated enzyme prodrug therapy. Exp Cell Res 313(13): 2958-2967, 2007. (Pubitemid 47126438)
23. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC and Carducci MA: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7(8): 2292-2300, 2001. (Pubitemid 32751627)
24. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD and Carducci MA: Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro-oncol 7(2): 177-182, 2005. (Pubitemid 40590517)
25. Taylor MD, Liu Y, Nagji AS, Theodosakis N and Jones DR: Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. J Thorac Cardiovasc Surg 139(5): 1224-1232, 32 e1, 2010.
26. Denlinger CE, Rundall BK and Jones DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128(5): 740-748, 2004. (Pubitemid 39388930)
27. Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R and Tesoriere G: SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12(7): 1327-1338, 2007. (Pubitemid 46890392)
28. Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM and Sezer O: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 80(2): 133-142, 2008.
29. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S and Roden RB: Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 15(2): 570-577, 2009.
30. Pitts TM, Morrow M, Kaufman SA, Tentler JJ and Eckhardt SG: Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 8(2): 342-349, 2009.
31. Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I, Assaf C and Sezer O: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol 82(6): 440-449, 2009.
32. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ and Zhao WL: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 23(8): 1507-1514, 2009.
33. Yu C, Friday BB, Yang L, Atadja P, Wigle D, Sarkaria J and Adjei AA: Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro Oncol 10(3): 309-319, 2008.
34. Nygren P, Fridborg H, Csoka K, Sundstrom C, de la Torre M, Kristensen J, Bergh J, Hagberg H, Glimelius B, Rastad J et al: Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 56(5): 715-720, 1994. (Pubitemid 24086775)
35. Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, Bergh A and Hedman H: LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer 128(12): 2843-2852, 2011.
36. Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Pezzella F, Bernards R and La Thangue NB: Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15(1): 57-66, 2009.
37. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, Ylstra B and Leenstra S: The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27(14): 2091-2096, 2008. (Pubitemid 351442747)
38. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM and Amrein PC: Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 14(5): 1446-1454, 2008. (Pubitemid 351413928)
39. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H and Richon VM: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23(17): 3923-3931, 2005. (Pubitemid 46218695)
40. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ and Belani CP: Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13(12): 3605-3610, 2007. (Pubitemid 46955122)
41. Loscher W: Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58(1): 31- 59, 1999.
42. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, Jaeckle K and Galanis E: Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-oncol 14(2): 215-221, 2012.
43. Rahman M, Deleyrolle L, Vedam-Mai V, Azari H, Abd-El-Barr M and Reynolds BA: The cancer stem cell hypothesis: failures and pitfalls. Neurosurgery 68(2): 531-545; discussion 45, 2011.
44. Westphal M and Lamszus K: The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 12(9): 495-508, 2011.